


What is claimed is:

1. A compound which is:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof, according to Claim 1, further comprising a pharmaceutically acceptable excipient.
3. A pharmaceutical composition according to Claim 2 suitable for oral administration, for intramuscular injection, or for subcutaneous injection.
4. Use of a compound or salt according to any of Claims 1-3 in the manufacture of a medicament for the treatment of HIV infection in a human.
5. The use according to Claim 4 wherein the said medicament is to be administered orally.
6. The use according to Claim 4 wherein the said medicament is to be administered via intramuscular injection.
7. The use according to Claim 4 wherein the said medicament further comprises use of at least one other agent in the manufacture of a medicament for the treatment of HIV infection in a human.
8. The use according to Claim 7 wherein the at least one other agent is selected from the group consisting of abacavir, atazanavir, bicitgravir, cabotegravir, dolutegravir, darunavir, doravirine, fostemsavir, lamivudine, maraviroc, rilpiverine, tenofovir disoproxil,, tenofovir, tenofovir afenamide, S-648414, GSK3640254, the antibody N6LS, and GSK3739937/VH3739937.

- CN1C=NC2=C1N(S(=O)(=O)OC)C=C2c3cc(Cl)ccc3N4C(=O)c5ccc(nc5N4Cc6ccc(F)c(F)c6)C(=O)NC(=O)C7C(F)C(F)C8C7C(F)C(F)C8

- 47

19. Use of the compound according to Claim 16 in the manufacture of a medicament for the treatment of HIV infection.
20. The use of Claim 19 wherein the medicament is to be used orally.
21. The use of Claim 19 wherein the medicament is to be used in an intramuscular injection.
22. The use of Claim 19 wherein the medicament is to be used in a subcutaneous injection.
23. The use of Claim 19 wherein the said medicament further comprises use of at least one other agent in the manufacture of a medicament for the treatment of HIV infection.
24. The use of Claim 23 wherein the at least one other agent is selected from a group consisting of abacavir, atazanavir, bictegravir, cabotegravir, dolutegravir, darunavir, doravirine, fostemsavir, lamivudine, maraviroc, rilpiverine, tenofovir disoproxil, tenofovir, tenofovir afenamide, S-648414, GSK3640254, the antibody N6LS, and GSK3739937/VH3739937.
25. The use of Claim 23 wherein the at least one other agent is selected from a group consisting of dolutegravir, lamivudine, fostemsavir, cabotegravir, the antibody N6LS, and GSK3739937/VH3739937.
26. The use of Claim 23 wherein the at least one other agent is cabotegravir.
27. The use of Claim 23 wherein the at least one other agent is dolutegravir.
28. A compound according to Claim 16 for use in therapy.
29. A compound according to Claim 16 for use in treating HIV infection.